Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922452 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
A Phase 1 study of Ischemic Stroke, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02922452 is a Phase 1 study of Ischemic Stroke that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02922452, a Phase 1 study of Ischemic Stroke, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the effect of dilitazem on the single-dose PK of BMS-986141 with parameters like Cmax, AUC(INF), and AUC(0-T).
Conditions Studied
Interventions
- DRUG BMS-986141
- DRUG Dilitazem
Study Locations (1)
Texas
- PPD Development - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-09 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02922452
The ClinicalTrials.gov registry entry for NCT02922452 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (99% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which BMS-986141 is the first listed.
NCT02922452 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02922452 about?
NCT02922452 is a clinical study titled "A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects". This study is to evaluate the effect of dilitazem on the single-dose PK of BMS-986141 with parameters like Cmax, AUC(INF), and AUC(0-T).
What is the current status of trial NCT02922452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-09. Estimated completion is 2016-11.
What conditions does trial NCT02922452 study?
This clinical trial studies the following conditions: Ischemic Stroke.
What interventions are being tested in trial NCT02922452?
The interventions under investigation include: BMS-986141 (DRUG), Dilitazem (DRUG).
Who is sponsoring clinical trial NCT02922452?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02922452 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Verapamil for Neuroprotection in Stroke
RECRUITING · Phase 1
-
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
ACTIVE NOT RECRUITING · Phase 1
-
A Study of NCS-01 in Patients With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 1
-
Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living
COMPLETED · Phase 1
-
The Capillary Index Score Trial
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.